CureTalks Launches New Talk Series on Contribution of Small Biotech Companies Towards Drug Development of Orphan Diseases

CureTalks launches its new series featuring biotech companies at the cutting edge of innovation and breakthrough research with the purpose of bringing their contributions to the fore and informing the patient community. This talk series will be hosted by Gary Petersen, our Myeloma talk cohost, panel member and editor of myelomasurvival.com. The talk series titled CureTalks with Gary, will discuss the drug development process, the journeys of the companies that are featured and their drug pipeline. 

We kickstarted the series with Cellectar, a clinical stage biopharmaceutical company focused on the discovery, development of drugs for the treatment of cancer. Cellectar, has a targeted universal drug conjugate with a potential to be used for many cancers. This drug conjugate, CLR131 was granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission and is currently being evaluated in a Phase 2 and Phase 1 studies. The drug conjugate works by delivering a radioactive, toxic compound directly to tumor cells, while limiting exposure to healthy cells.

Gary Petersen talked to James Caruso, CEO and Jarrod Longcor of Cellectar Biosciences about product development, clinical trials, special challenges of a small biotech in the current investment environment and some of the innovative products in the pipeline. 

Check out the discussion here: https://www.curetalks.com/next-generation-targeted-cancer-therapies-the-cellectar-story/

We are very excited and looking forward to featuring drug development stories and journeys of the small biotech companies. On our next episode of CureTalks with Gary, we are talking to SELLAS Life Sciences.

Stay Tuned!



Shares